{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:39Z","timestamp":1793506599384,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02876-z","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:04:14Z","timestamp":1781708654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitors with neoadjuvant chemoradiotherapy in proficient MMR rectal cancer: systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Reza","family":"Ghalehtaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Abyaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Mahdi","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Seddighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Kolahdouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"7","key":"2876_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen Y-J, Ciombor KK, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874\u2013901.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"2876_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41575-020-0275-y","volume":"17","author":"DS Keller","year":"2020","unstructured":"Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Reviews Gastroenterol Hepatol. 2020;17(7):414\u201329.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"10","key":"2876_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","volume":"20","author":"AB Benson","year":"2022","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen Y-J, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139\u201367.","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"2876_CR4","doi-asserted-by":"publisher","first-page":"e70291","DOI":"10.1002\/cam4.70291","volume":"13","author":"R Ghalehtaki","year":"2024","unstructured":"Ghalehtaki R, Nourbakhsh F, Abyaneh R, Sharifian A, Pashapour-Khoyi S, Aghili M, et al. Optimal Sequence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: An Evidence\u2010Based Review. Cancer Med. 2024;13(19):e70291.","journal-title":"Cancer Med"},{"issue":"9","key":"2876_CR5","doi-asserted-by":"publisher","first-page":"e1555","DOI":"10.1002\/onco.13824","volume":"26","author":"S Liu","year":"2021","unstructured":"Liu S, Jiang T, Xiao L, Yang S, Liu Q, Gao Y, et al. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021;26(9):e1555\u201366.","journal-title":"Oncologist"},{"issue":"12","key":"2876_CR6","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s11605-022-05463-1","volume":"26","author":"N Horesh","year":"2022","unstructured":"Horesh N, Freund MR, Garoufalia Z, Gefen R, Nagarajan A, Suarez E, et al. Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer. J Gastrointest Surg. 2022;26(12):2579\u201384.","journal-title":"J Gastrointest Surg"},{"issue":"15","key":"2876_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3390\/cancers17152416","volume":"17","author":"MC Barba","year":"2025","unstructured":"Barba MC, De Franco P, Russo D, Cavalera E, Ciurlia E, De Matteis S, et al. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Evaluation of Sequencing, Response, and Toxicity in a Single-Institution Cohort. Cancers. 2025;17(15):2416.","journal-title":"Cancers"},{"issue":"8","key":"2876_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.23.01196","volume":"42","author":"E Fokas","year":"2024","unstructured":"Fokas E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, Buyse M, R\u00f6del C. Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited. J Clin Oncol. 2024;42(8):872\u20135.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2876_CR9","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00384-020-03633-8","volume":"35","author":"RM Engel","year":"2020","unstructured":"Engel RM, Oliva K, Koulis C, Yap R, McMurrick PJ. Predictive factors of complete pathological response in patients with locally advanced rectal cancer. Int J Colorectal Dis. 2020;35(9):1759\u201367.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"2876_CR10","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"1","key":"2876_CR11","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.","journal-title":"Nat Commun"},{"issue":"25","key":"2876_CR12","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair\u2013Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363\u201376.","journal-title":"N Engl J Med"},{"issue":"18","key":"2876_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMc2210175","volume":"387","author":"DJ Papke","year":"2022","unstructured":"Papke DJ, Yurgelun MB, Noffsinger AE, Turner KO, Genta RM, Redston M. Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas. N Engl J Med. 2022;387(18):1714\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"2876_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687\u201395.","journal-title":"J Clin Investig"},{"issue":"6","key":"2876_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","volume":"17","author":"C Chen","year":"2021","unstructured":"Chen C, Liu Y, Cui B. Effect of radiotherapy on T cell and PD-1 \/ PD-L1 blocking therapy in tumor microenvironment. Hum Vaccines Immunotherapeutics. 2021;17(6):1555\u201367.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"3","key":"2876_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1\u201348.","journal-title":"J Stat Softw"},{"key":"2876_CR17","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"issue":"9","key":"2876_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"issue":"5","key":"2876_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.esmoop.2023.101824","volume":"8","author":"E Grassi","year":"2023","unstructured":"Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, et al. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open. 2023;8(5):9.","journal-title":"ESMO Open"},{"issue":"1","key":"2876_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41698-025-01018-0","volume":"9","author":"Z Hou","year":"2025","unstructured":"Hou Z, Liao L, Xiao W, Sui Q, Han K, Xiao B, et al. Neoadjuvant chemoradiotherapy plus sintilimab in pMMR\/MSS rectal cancer patients with PD-L1 TPS\u2009\u2265\u20091% or CPS\u2009\u2265\u20091: an open-label, prospective, phase II study. npj Precision Oncol. 2025;9(1):237.","journal-title":"npj Precision Oncol"},{"issue":"5","key":"2876_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","volume":"159","author":"Y Li","year":"2024","unstructured":"Li Y, Pan C, Gao Y, Zhang L, Ji D, Cui X, et al. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer. JAMA Surg. 2024;159(5):529\u201337.","journal-title":"JAMA Surg"},{"issue":"11","key":"2876_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jitc-2021-003554","volume":"9","author":"ZY Lin","year":"2021","unstructured":"Lin ZY, Cai M, Zhang P, Li G, Liu T, Li X, et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. 2021;9(11):10.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2876_CR23","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-25-0705","volume":"31","author":"M Michael","year":"2025","unstructured":"Michael M, Wong R, Gill S, Strickland AH, Pavlakis N, Shapiro JD, et al. The Ave-Rec Trial: Phase II Trial of PDL1\/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4\/N1-2 Rectal Cancer. Clin Cancer Res. 2025;31(16):3452\u201362.","journal-title":"Clin Cancer Res"},{"key":"2876_CR24","doi-asserted-by":"publisher","first-page":"115428","DOI":"10.1016\/j.ejca.2025.115428","volume":"222","author":"A Shamseddine","year":"2025","unstructured":"Shamseddine A, Turfa R, Chehade L, Zeidan YH, El Husseini Z, Kreidieh M, et al. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study. Eur J Cancer. 2025;222:115428.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2876_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41416-024-02730-7","volume":"131","author":"Y Tsukada","year":"2024","unstructured":"Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, et al. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Br J Cancer. 2024;131(2):283\u20139.","journal-title":"Br J Cancer"},{"key":"2876_CR26","volume-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: A phase II PRECAM experimental study","author":"F Wang","year":"2024","unstructured":"Wang F, Lai C, Lv Y, Zhang F, Shi L, Wang Y, et al. Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: A phase II PRECAM experimental study. London, England: International journal of surgery; 2024."},{"key":"2876_CR27","doi-asserted-by":"crossref","unstructured":"Xia F, Chen Y, Zhou D, Wan J, Shen L, Wang Y, et al. Organ preservation via immunotherapy-based total neoadjuvant therapy in early low rectal cancer (TORCH-E): a multicenter, open-label, single-arm, phase II study. Clin Cancer Res. 2025:OF1\u20139.","DOI":"10.1158\/1078-0432.30750162"},{"issue":"28","key":"2876_CR28","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.23.02261","volume":"42","author":"F Xia","year":"2024","unstructured":"Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). J Clin Oncol. 2024;42(28):3308\u201318.","journal-title":"J Clin Oncol"},{"key":"2876_CR29","doi-asserted-by":"crossref","unstructured":"Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct Target Ther. 2024;9(1).","DOI":"10.1038\/s41392-024-01762-y"},{"issue":"8","key":"2876_CR30","doi-asserted-by":"publisher","first-page":"e2527769","DOI":"10.1001\/jamanetworkopen.2025.27769","volume":"8","author":"J Laengle","year":"2025","unstructured":"Laengle J, Kuehrer I, Kulu A, Kabiljo J, Ammon D, Zirnbauer R, et al. Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial. JAMA Netw open. 2025;8(8):e2527769\u20132527769.","journal-title":"JAMA Netw open"},{"issue":"10","key":"2876_CR31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","volume":"35","author":"ZY Lin","year":"2024","unstructured":"Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882\u201391.","journal-title":"Ann Oncol"},{"issue":"8","key":"2876_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, et al. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(8):1225\u201330.","journal-title":"JAMA Oncol"},{"key":"2876_CR33","doi-asserted-by":"crossref","unstructured":"Tang Y, Li H-Y, Wei LC, Li N, Zhang WJ, Lu YF, et al. Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II). Med. 2025.","DOI":"10.1016\/j.medj.2025.100807"},{"key":"2876_CR34","doi-asserted-by":"crossref","unstructured":"Tian F, Dai H, Sha D, Yu Y, Jing H, Sun C, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine\u2013oxaliplatin versus short-course radiotherapy followed by capecitabine\u2013oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. Lancet Oncol. 2025.","DOI":"10.1016\/S1470-2045(25)00286-4"},{"issue":"9","key":"2876_CR35","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","volume":"42","author":"WW Xiao","year":"2024","unstructured":"Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial. Cancer Cell. 2024;42(9):1570\u2013e15811574.","journal-title":"Cancer Cell"},{"issue":"2","key":"2876_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","volume":"31","author":"Y Yang","year":"2025","unstructured":"Yang Y, Pang K, Lin G, Liu X, Gao J, Zhou J, et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nat Med. 2025;31(2):449\u201356.","journal-title":"Nat Med"},{"issue":"4","key":"2876_CR37","first-page":"483","volume":"24","author":"JA Nieuwstraten","year":"2025","unstructured":"Nieuwstraten JA, van Geffen EGM, Leenders MWH, Tanis PJ, Kusters M, Aukema TS. Incidence of Mismatch Repair Deficiency in Rectal Cancer and Response to Neoadjuvant Treatment. Clin Colorectal Cancer. 2025;24(4):483\u201391.","journal-title":"Clin Colorectal Cancer"},{"key":"2876_CR38","unstructured":"Audisio A, Gallio C, Velenik V, Meillat H, Ruiz-Garcia E, Riesco MC, et al. Total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2025."},{"issue":"10","key":"2876_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Wang W, Hu S, Jia B, Tuo B, Sun H, et al. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis. 2023;14(10):679.","journal-title":"Cell Death Dis"},{"issue":"24","key":"2876_CR40","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.21037\/atm-22-6049","volume":"10","author":"N-H Wang","year":"2022","unstructured":"Wang N-H, Lei Z, Yang H-N, Tang Z, Yang M-Q, Wang Y, et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Annals Translational Med. 2022;10(24):1406.","journal-title":"Annals Translational Med"},{"issue":"4","key":"2876_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.7150\/jca.132006","volume":"17","author":"L Yang","year":"2026","unstructured":"Yang L, Wang K, Zeng W, Lu Y, Sheng H, Xiong H, et al. Myeloid-Derived Suppressor Cells and Radiotherapy: Regulation and Clinical Implications. J Cancer. 2026;17(4):855\u201380.","journal-title":"J Cancer"},{"key":"2876_CR42","doi-asserted-by":"publisher","first-page":"108017","DOI":"10.1016\/j.intimp.2021.108017","volume":"99","author":"N Liu","year":"2021","unstructured":"Liu N, Shan F, Ma M. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. Int Immunopharmacol. 2021;99:108017.","journal-title":"Int Immunopharmacol"},{"key":"2876_CR43","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.ctro.2025.101018","volume":"54","author":"S Salarvand","year":"2025","unstructured":"Salarvand S, Abyaneh R, Raee A, Yaghooti-Khorasani M, Mohammadjani F, Nili F, et al. CD8-positive lymphocyte infiltration as a marker of anti-tumor immune response in rectal cancer: pre- and post-neoadjuvant radiotherapy comparison. Clin Translational Radiation Oncol. 2025;54:101018.","journal-title":"Clin Translational Radiation Oncol"},{"issue":"4","key":"2876_CR44","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766\u201372.","journal-title":"Ann Surg"},{"key":"2876_CR45","doi-asserted-by":"publisher","first-page":"1392499","DOI":"10.3389\/fimmu.2024.1392499","volume":"15","author":"L Yang","year":"2024","unstructured":"Yang L, Cui X, Wu F, Chi Z, Xiao L, Wang X, et al. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review. Front Immunol. 2024;15:1392499.","journal-title":"Front Immunol"},{"key":"2876_CR46","doi-asserted-by":"publisher","first-page":"1570467","DOI":"10.3389\/fphar.2025.1570467","volume":"16","author":"J Yu","year":"2025","unstructured":"Yu J, Wang Z, Li M, Zhu H, Tang X, Luan K, et al. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1570467.","journal-title":"Front Pharmacol"},{"key":"2876_CR47","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu Y, Guan X, Liu X, Tang Y, Zhang W-W, et al. Neoadjuvant immunotherapy and chemoradiotherapy for mismatch repair proficient locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2025.","DOI":"10.1016\/j.radonc.2025.111073"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02876-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:52:34Z","timestamp":1787784754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2876"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02876-z","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}